Baudax Bio, Inc.

Equities

BXRXQ

US07160F4046

Biotechnology & Medical Research

Delayed OTC Markets 03:59:10 2024-03-27 pm EDT 5-day change 1st Jan Change
0.016 USD -5.88% Intraday chart for Baudax Bio, Inc. 0.00% -27.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Baudax Bio, Inc. Filed for Bankruptcy CI
Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Baudax Bio, Inc.(OTCPK:BXRX) dropped from S&P TMI Index CI
Baudax Bio, Inc.(OTCPK:BXRX) dropped from NASDAQ Composite Index CI
Baudax Bio, Inc. to Initiate TI-168 Clinical Development CI
Sector Update: Health Care Stocks Advancing in Late Afternoon Trading MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
Baudax Bio Appoints Natalie McAndrew as Interim Finance Chief MT
Baudax Bio, Inc. Announces Board Changes CI
Baudax Bio, Inc. Announces Chief Financial Officer Changes CI
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected MT
Top Premarket Decliners MT
Baudax Bio, Inc. Announces Orphan Drug Designation Granted by U.S. Fda for Ti-168 for the Treatment of Hemophilia A with Inhibitors CI
Sector Update: Health Care Stocks Rising in Late Afternoon Trading MT
Sector Update: Health Care MT
Top Midday Gainers MT
Baudax Bio Shares Double After Orphan Drug Designation for TI-168 DJ
Wall Street Set to Open Flat; Q2 GDP Rises 2.1%; Jobless Claims Lower Than Expected MT
Baudax Bio Files Registration Statement on Behalf of Selling Stockholder MT
Baudax Bio, Inc. Enters into Amendment No. 7 to the Credit Agreement CI
Baudax Bio, Inc. announced that it expects to receive $50 million in funding from Alumni Capital LP CI
Baudax Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Baudax Bio, Inc., Baudax Bio N.A. LLC, Baudax Bio Limited and TeraImmune, LLC enter Amendment No. 1 to Forbearance Agreement and Amendment No. 6 to Credit Agreement CI
Baudax Bio, Inc. Appoints Yong Chan Kim as A Member of the Board CI
Certain Common Stock of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUL-2023. CI
Chart Baudax Bio, Inc.
More charts
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. It is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. It is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings